Glaukos (NYSE:GKOS) Given “Buy” Rating at BTIG Research

BTIG Research restated their buy rating on shares of Glaukos (NYSE:GKOS) in a research note issued to investors on Wednesday morning,Benzinga reports. BTIG Research currently has a $131.00 target price on the medical instruments supplier’s stock.

A number of other analysts have also weighed in on the company. UBS Group increased their target price on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. Needham & Company LLC raised their price target on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research note on Wednesday. Citigroup lifted their price objective on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Stifel Nicolaus upped their target price on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Truist Financial lifted their price target on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $133.69.

Glaukos Stock Performance

Glaukos stock opened at $121.33 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The firm has a market capitalization of $6.97 billion, a P/E ratio of -37.22 and a beta of 0.70. Glaukos has a 1-year low of $73.16 and a 1-year high of $161.78. The company’s 50-day moving average is $114.92 and its 200 day moving average is $98.50.

Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 6.75%. The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. During the same period in the prior year, the company posted ($0.40) EPS. The company’s quarterly revenue was up 35.6% compared to the same quarter last year. Research analysts forecast that Glaukos will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total transaction of $536,350.00. Following the completion of the sale, the director directly owned 34,905 shares of the company’s stock, valued at approximately $3,744,259.35. This represents a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the firm’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the sale, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. This represents a 54.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 310,315 shares of company stock worth $36,011,634. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Several institutional investors have recently bought and sold shares of the company. Summit Global Investments increased its position in shares of Glaukos by 151.3% during the fourth quarter. Summit Global Investments now owns 7,052 shares of the medical instruments supplier’s stock worth $796,000 after purchasing an additional 4,246 shares in the last quarter. Mackenzie Financial Corp increased its position in Glaukos by 331.8% during the 4th quarter. Mackenzie Financial Corp now owns 15,404 shares of the medical instruments supplier’s stock valued at $1,756,000 after buying an additional 11,837 shares in the last quarter. Empowered Funds LLC purchased a new stake in Glaukos in the fourth quarter valued at about $217,000. XTX Topco Ltd acquired a new stake in Glaukos in the fourth quarter worth about $308,000. Finally, SummitTX Capital L.P. grew its stake in shares of Glaukos by 83.9% during the fourth quarter. SummitTX Capital L.P. now owns 29,534 shares of the medical instruments supplier’s stock worth $3,335,000 after acquiring an additional 13,476 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record Q4 net sales of $143.1M, up ~36% year-over-year, well above Street revenue expectations — a clear top-line beat that supports growth narrative. Business Wire: Q4 Results
• Positive Sentiment: Company raised 2026 revenue guidance to $600–$620M, signaling management confidence in traction from new products and helping to re-rate near-term sales expectations. Zacks: Raises 2026 Outlook
• Positive Sentiment: Analysts have been lifting forecasts and reconfirming coverage (BTIG reaffirmed Buy with a $131 target), reflecting the favorable reaction to revenue/guidance. Analyst support is helping momentum. Benzinga: Analysts Boost Forecasts
• Neutral Sentiment: Earnings call/transcript highlights reiterate record sales and product momentum (iDose TR, Epioxa mentioned as growth drivers); useful color for investors but largely confirms what was in the release. MSN: Q4 Earnings Call Transcript
• Negative Sentiment: EPS missed estimates: GAAP loss of $0.28/sh vs. consensus loss of $0.22 and Glaukos remains unprofitable with a wider operating loss — a reminder that growth is expensive and near-term profitability risks remain. Zacks: Q4 Loss, Beats Revenue

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.